Partner Therapeutics secures FDA approval for Bizengri

​Partner Therapeutics has received FDA approval for Bizengri to treat adults with advanced, unresectable or metastatic cholangiocarcinoma harbouring an NRG1 gene fusion and who have progressed on or after prior systemic therapy.

The post Partner Therapeutics secures FDA approval for Bizengri appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

HeartBeam commences pilot study of new 12-lead ECG patch
Inhibrx announces positive interim results from HexAgon trial
Latest foreign investment in UK highlights underserved potential of primary care technology
CoMira concludes lease agreement for plant in Sudair Industrial City, Saudi Arabia
Day One concludes patient enrolment for tovorafenib’s FIREFLY-2 trial

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us